P2RY12 and epistaxis: As shown in Table 2, we observed 2/25 major bleeding incidents in the cangrelor group (access site bleeding on day 1 in 1 patient and inguinal bleeding due to shearing of a venous side branch after cooling catheter insertion in another patient) and 4/17 major bleeding incidents with oral P2Y12 inhibitors (severe epistaxis on day 1, pulmonary bleeding in the first three days, hematothorax and access site bleeding at the femoral vein and jugular vein, respectively).